It remains desirable to screen uterine cervix cancer patients by GRPR protein expression level as an enrichment approach for clinical trials evaluating the 212Pb-DOTAM-GRPR1 radiopharmaceutical. The gene discussed is GRPR; the disease is cervical cancer.